You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Product menu

The evidence for paediatric universal vaccination

Universal vaccination has successfully helped reduce the burden of hepatitis A in several countries1–3

Why are UV programmes for hepatitis A needed?

WHO recommends that vaccination against hepatitis A virus be introduced into UV programmes for children aged ≥12 months, if indicated based on:1

  • An increasing trend over time of acute hepatitis A disease, including severe disease, among older children, adolescents or adults
  • Changes in the endemicity from high to intermediate
  • Considerations of cost-effectiveness

Hepatitis A UV programmes in countries with intermediate endemicity can help protect individuals from infection and disease and reduce virus circulation3

Find out more about hepatitis A and Havrix Junior

Long-term protection

Discover the benefits of Havrix Junior

The burden of hepatitis A

Find out more about the hepatitis A burden

The shifting endemicity of hepatitis A

Discover what shifting endemicity means for patients

HAV, hepatitis A virus; UV, universal vaccination; WHO, World Health Organization

Havrix Junior can be administered to children and adolescents aged 1–15 years.4 Havrix can be administered to adults 16 years and over.5 Both are administered in a primary dose with a booster dose recommended 6–12 months after primary immunisation. The vaccines provide active immunisation against infections caused by hepatitis A in both age groups4,5

**Primary immunisation consists of a single dose given intramuscularly. This provides anti-HAV antibodies for at least one year. In order to obtain more persistent immunity, for at least 10 years, a booster dose is recommended between 6 and 12 months after primary immunisation.4 Single-dose UV programmes follow WHO recommendations1
†From a mean of 50.4 per 100,000 between 1993–1998, to a mean of <1.0 per 100,000 between 2008–201214

References

  1. World Health Organization. Wkly Epidemiol Rec 2022; 97:493–512.
  2. Chodick G et al. J Viral Hepatitis 2008; 15:62–65.
  3. Stuurman AL et al. Hum Vaccin Immunother 2017; 13:724–736.
  4. Havrix Junior SmPC, January 2022.
  5. Havrix Monodose SmPC, January 2022.
  6. de Brito WI et al. Braz J Infect Dis 2018; 22:166–170.
  7. Gobierno de Chile. Informe Preliminar de Cobertura Nacional de Inmunizaciones año 2021. Available at: https://vacunas.minsal.cl/wp-content/uploads/2022/04/Informe-de-Coberturas_2021_enero_diciembre.pdf (Accessed April 2023).
  8. Mayorga O et al. J Infect Dis 2016; 214:1498–1506.
  9. Domínguez A et al. Vaccine 2008; 26:1737–1741.
  10. Hanna JN et al. Med J Aust 2004; 181:482–485.
  11. Fisenka EG et al. J Viral Hepat 2008; 15:57–61.
  12. Lopalco PL et al. Emerg Infect Dis 2008; 14:526–528.
  13. Estripeaut D et al. Vaccine 2015; 33:3200–3207.
  14. Levine H et al. Euro Surveill 2015; 20:pii=21040.

For more information, please refer to the prescribing information or contact GlaxoSmithKline
via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

GlaxoSmithKline Biologicals SA. Rixensart, Belgium
© 2023 GSK group of companies or its licensor
Trademark is owned by or licensed to the GSK group of companies

PM-RCH-HAV-WCNT-230002 | Date of preparation: November 2023